Manufacturing agreement met for phase II cancer vaccine.

2003 NOV 5 - (NewsRx.com & NewsRx.net) -- Prima Biomed Limited announced that its subsidiary Cancer Vac has entered into an agreement with Progen Industries Ltd (PGLAF) to commence the scale up manufacture for the therapeutic vaccine in its phase II clinical trial.

Marcus Clark, chief executive officer of Prima Biomed, said, "We are very pleased that Progen will undertake the scale up activities to produce a Good Manufacturing Practice grade of therapeutic vaccine.

"It is essential this activity be performed according to Therapeutic Goods Administration regulatory standards so it will also meet FDA (U.S. Food and Drug Administration) requirements, an essential element of our licensing package into North America."

"Progen has developed a broad set of contract manufacturing capabilities with clients spanning Australia, New Zealand, and the United States. In addition, they have their own manufacturing and clinical development expertise in the cancer sector with their lead compound PI-88 in multiple international clinical trials. We are very happy to have Progen involved with us."

Progen's managing director, Lewis Lee commented, "Our contract manufacturing business continues to provide a valuable service to an expanding range ...